Investment
Features
FeesSafety
Academy
More
Pluang+

Compare American States Water Company (AWR) vs BridgeBio Pharma Inc (BBIO) Price & Performance

American States Water CompanyTrade
BridgeBio Pharma IncTrade

Price performance (Past 24H)

Key statistics

American States Water Company vs BridgeBio Pharma Inc — how do they compare? American States Water Company trades at $87.83 (market cap $3.47B), while BridgeBio Pharma Inc trades at $83.26 (market cap $16.36B). The key difference: BridgeBio Pharma Inc is far larger — about 4.7× American States Water Company's market cap, and American States Water Company pays a 2.49% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.

AWRBBIO
Market Cap
$3.47B$16.36B
Sector
UtilitiesHealth
52-Week High
$89.28$90.17
52-Week Low
$70.10$47.29
Enterprise Value
$4.37B$18.14B
Dividend Yield
2.49%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

American States Water Company

No Aura AI signal available yet.

BridgeBio Pharma Inc

BridgeBio Pharma (BBIO) trades at $84.67, up 0.22% today, with a bullish technical signal and strong analyst consensus. Despite missing Q2 2026 EPS estimates with a loss of $0.78 per share, revenue beat expectations as Attruby sales surged 311% year-over-year. The company maintains a high gross margin of 94.44% but reports negative net income and cash flow from operations, reflecting its growth investment phase.

The outlook is optimistic due to multiple late-stage pipeline catalysts, including three potential product launches by mid-2027 and an FDA decision on encaleret by May 2027. Risks include sustained cash burn, high debt of $1.72 billion, and clinical trial execution. The consensus price target of $104.56 implies significant upside if commercial execution succeeds.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About American States Water Company

American States Water provides water and electric services to over one million people in the U.S. It also manages water and wastewater systems for various military bases under long-term privatization contracts.

Read more on AWR

About BridgeBio Pharma Inc

BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.

Read more on BBIO